<DOC>
	<DOCNO>NCT01089140</DOCNO>
	<brief_summary>Investigation tranexamic acid ( TXA ) reduce perioperative blood loss transfusion requirement pediatric patient secondary scoliosis undergo posterior spinal fusion .</brief_summary>
	<brief_title>Non-Idiopathic Scoliosis Treated With Tranexamic Acid</brief_title>
	<detailed_description>To investigate whether tranexamic acid ( TXA ) reduce perioperative blood loss transfusion requirement pediatric patient secondary scoliosis undergo posterior spinal fusion.In addition determination optimal TXA dose perioperative reduction blood loss transfusion requirement well evaluate use thromboelastography ( TEG ) measure coagulation fibrinolysis pediatric patient secondary scoliosis undergo posterior spinal fusion ( may help guide blood product therapy ) . The investigation determine effect TXA TEG profile whether plasminogen activator inhibitor-1 ( PAI-1 ) level affect bleed transfusion requirement scoliosis surgery . Finally investigate whether PAI-1 level affect bleed response TXA scoliosis surgery .</detailed_description>
	<mesh_term>Scoliosis</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Children secondary scoliosis undergo posterior spinal fusion 1 . Known bleed disorder may increase risk bleed 2 . Current antifibrinolytic therapy patient may bleed less 3 . Patient family history thromboembolic disease may potential risk thrombosis 4 . Use NSAIDS within 5 day surgery may increase risk bleed 5 . Known allergy TXA 6 . History renal insufficiency TXA renally excrete 7 . Colour vision disturbance</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>pediatrics</keyword>
	<keyword>scoliosis</keyword>
	<keyword>tranexamic acid</keyword>
	<keyword>Investigating non-idiopathic scoliosis</keyword>
</DOC>